Ghana will strengthen its capacity to solve complex criminal cases, identify disaster victims, and resolve disputed family relationships by establishing a national Human Identification Laboratory at the Noguchi Memorial Institute for Medical Research.
The facility, popularly known as the DNA Laboratory, will provide local DNA testing services for forensic investigations, disaster victim identification, paternity and maternity disputes, as well as inheritance-related cases, reducing the country’s reliance on foreign laboratories for specialised analysis.
President John Dramani Mahama, who commissioned the facility alongside new vaccine research and development laboratories, said the investment would address a longstanding gap in Ghana’s forensic and emergency response systems.
He recalled that following the August 2025 helicopter crash that claimed eight lives, Ghana had to transport tissue samples recovered from the accident scene to South Africa for DNA analysis, leaving families waiting several days for identification results.
Describing the experience as a moment of shame for the country, he said the new laboratory would enable Ghana to manage similar situations with greater speed, competence and independence.
Health Minister, Hon. Kwabena Mintah Akandoh, said the facility was established in response to the President’s directive following the helicopter disaster. He explained that although Ghana had qualified scientists, the country lacked the specialised equipment needed to conduct DNA analysis locally.
The Minister also said the accompanying vaccine research laboratories would strengthen Ghana’s ability to train vaccine producers locally, with the first vaccines bottled in the country expected on the market in 2027.
Chief Executive Officer of the National Vaccine Institute, Dr Sodzi Sodzi-Tettey, said Ghana was making progress towards establishing a sustainable vaccine manufacturing ecosystem.
He disclosed that the first of three bulk substances required for the targeted vaccine production was already in the country at Atlantic LifeSciences, while government was pursuing long-term procurement arrangements to guarantee a market for locally manufactured vaccines.
The two projects form part of Ghana’s broader drive to strengthen domestic scientific capacity, improve health security and reduce dependence on foreign expertise and supplies.



















